JPH10508608A - 溶融押出しによる経口投与可能なオピオイド製剤 - Google Patents
溶融押出しによる経口投与可能なオピオイド製剤Info
- Publication number
- JPH10508608A JPH10508608A JP8515537A JP51553796A JPH10508608A JP H10508608 A JPH10508608 A JP H10508608A JP 8515537 A JP8515537 A JP 8515537A JP 51553796 A JP51553796 A JP 51553796A JP H10508608 A JPH10508608 A JP H10508608A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- release
- opioid
- hours
- therapeutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/02—Making granules by dividing preformed material
- B29B9/06—Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.治療活性薬、アルキルセルロース、アクリルおよびメタクリル酸ポリマーな らびにコポリマー、シェラック、ゼイン、水添ヒマシ油、水添植物油、ならびに これらの混合物からなる群から選択される1以上の疎水性物質、そして融点が30 −200℃であり、遅延効果をさらに与える、天然および合成ワックス、脂肪酸、 脂肪族アルコールおよびこれらの混合物からなる群から選択される1以上の疎水 性可融性担体、の溶融押出し配合物を、所望の治療効果を与えるのに有効な量の 治療活性薬を含有し、約8−約24時間の期間、該治療活性薬の持続放出をもたら す単位用量に分割した、持続放出性医薬製剤。 2.押出し物がストランド状マトリックスからなり、約0.1−約5 mmの長さの多 重粒子に切断される、請求の範囲1記載の製剤。 3.押出し物が約0.1−約5 mmの直径を有する、請求の範囲1記載の製剤。 4.治療活性薬がオピオイド鎮痛剤である、請求の範囲1記載の製剤。 5.オピオイド鎮痛剤が、アルフェンタニル、アリルプロジン、アルファプロジ ン、アニレリジン、ベンジルモルヒネ、ベジトラミド、ブプレノルフィン、ブト ルファノール、クロニタゼン、コデイン、シクラゾシン、デソモルヒネ、デキス トロモラアミド、デゾシン、ジアンプロミド、ジヒドロコデイン、ジヒドロモル ヒネ、ジメノキサドール、ジメフェプタノール、ジメチルチアンブテン、ジオキ サフェチルブチレート、ジピパノン、エプタゾシン、エトヘプタジン、エチルメ チルチアンブテン、エチルモルヒネ、エトニタゼン、フェンタニル、ヘロイン、 ヒドロコドン、ヒドロモルホン、ヒドロキシペチジン、イソメタドン、ケトベミ ドン、レバロルファン、レボルファノール、レボフェナシルモルファン、ロフェ ンタニル、メペリジン、メプタジノール、メタゾシン、メタドン、メトポン、モ ルヒネ、ミロフィン、ナルビュフィン、ナルセイン、ニコモルヒネ、ノルレボル ファノール、ノルメタドン、ナロルフィン、ノルモルヒネ、ノルピパノン、オピ ウム、オキシコドン、オキシモルフォン、パパベレツム、ペンタゾシン、フェナ ドキソン、フェノモルファン、フェナゾシン、フェノペリジン、ピミノジン、ピ リトラミド、プロフェプタジン、プロメドール、プロペリジン、プロピラム、プ ロポキシフェン、スフェンタニル、トラマドール、 チリジン、これらの塩およびこれらの混合物からなる群から選択される、請求の 範囲4記載の製剤。 6.オピオイド鎮痛剤がモルヒネ、コデイン、ヒドロモルホン、ヒドロコドン、 オキシコドン、オキシモルホン、ジヒドロコデイン、ジヒドロモルヒネ、トラマ ドールおよびこれらの混合物からなる群から選択される、請求の範囲1記載の押 出し物。 7.治療効果を与えるのに有効な量の多重粒子を含む単位用量が1つのゼラチン カプセル内に含まれている、請求の範囲2記載の製剤。 8.治療効果を与えるのに有効な量の多重粒子を含む単位用量が1つの錠剤に圧 縮されている、請求の範囲2記載の製剤。 9.治療活性薬がトラマドールである、請求の範囲8記載の製剤。 10.治療活性薬が、モルヒネ、コデイン、ヒドロモルホン、ヒドロコドン、オキ シコドン、オキシモルホン、ジヒドロコデイン、ジヒドロモルヒネ、トラマドー ルおよびこれらの混合物からなる群から選択されるオピオイド鎮痛剤である、請 求の範囲7記載の製剤。 11.37℃、900 mlの水性緩衝液(pH1.6−7.2)中100 prm において、USP Padd leまたはBasket Method によって評価した場合、重量で1時間後に約1−約42.5 %のオピオイド放出、2時間後に約5−約65%のオピオイド放出、4時間後に約1 5−約85%のオピオイド放出、6時間後に約20−約90%のオピオイド放出、12時 間後に約35−約95%のオピオイド放出、18時間後に約45−約100%のオピオイド 放出、そして24時間後に約55−約100%のオピオイド放出、のin vitroの放出を 与える、請求の範囲10記載の製剤。 12.経口投与の約2−約8時間後、好ましくは投与の約4−約6時間後に血漿レ ベルのピークを与える、請求の範囲10記載の製剤。 13.約4−約12時間のW50を与える、請求の範囲10記載の製剤。 14.in vivo で得られる血漿レベルのピークが経口投与の約2−約8時間後に生 じるような、経口投与後にオピオイドの血漿濃度の急速な初期上昇速度を与える 、請求の範囲10記載の製剤。 15.吸収半減期が(絶食状態において)経口投与の約1−約8時間後となるよう な、経口投与後にオピオイドの血漿濃度の急速な初期上昇速度を与える、請求の 範囲10記載の製剤。 16.37℃、900 mlの水性緩衝液(pH1.6−7.2)中100 prm において、USP Padd leまたはBasket Method によって評価した場合、重量で1時間後に約12.5−約42 .5%のオピオイド放出、2時間後に約25−約65%のオピオイド放出、4時間後に 約45−約85%のオピオイド放出、そして8時間後に約60%以上のオピオイド放出 、のin vitroの放出を与える、請求の範囲10記載の製剤。 17.押出し配合物が実質的に非多孔質である、請求の範囲1記載の製剤。 18.治療活性薬に(1)アルキルセルロース、アクリルおよびメタクリル酸ポリ マーならびにコポリマー、シェラック、ゼイン、水添ヒマシ油、水添植物油、な らびにこれらの混合物からなる群から選択される疎水性物質、および(2)天然 および合成ワックス、脂肪酸、脂肪族アルコールおよびこれらの混合物からなる 群から選択される疎水性可融性担体であって、この遅延物質は融点が30−200℃ であり、治療活性薬の放出をさらに遅延させるのに十分な量が含有されている疎 水性可融性担体、を配合し、 混合物を押し出すのに十分な程度軟化させるのに十分な温度に該配合物を加 熱し、 該加熱混合物を直径0.1−3 mmのストランドとして押し出し、 該ストランドを冷却し、そして、 該ストランドを分割して、長さ0.1−5 mmの該押出し物の非球形多重粒子を 形成させ、そして、 該非球形多重粒子を、該治療活性薬の有効な量を含有し、約8−約24時間の 期間、該治療活性薬の持続放出をもたらす単位用量に分割する、 ことからなる、経口投与に好適な持続放出性押出し医薬品の製造方法。 19.治療活性薬が、アルフェンタニル、アリルプロジン、アルファプロジン、ア ニレリジン、ベンジルモルヒネ、ベジトラミド、ブプレノルフィン、ブトルファ ノール、クロニタゼン、コデイン、シクラゾシン、デソモルヒネ、デキストロモ ラミド、デゾシン、ジアンプロミド、ジヒドロコデイン、ジヒドロモルヒネ、ジ メノキサドール、ジメフェプタノール、ジメチルチアンブテン、ジオキ サフェチルブチレート、ジピパノン、エプタゾシン、エトヘプタジン、エチルメ チルチアンブテン、エチルモルヒネ、エトニタゼン、フェンタニル、ヘロイン、 ヒドロコドン、ヒドロモルホン、ヒドロキシペチジン、イソメタドン、ケトベミ ドン、レバロルファン、レボルファノール、レボフェナシルモルファン、ロフェ ンタニル、メペリジン、メプタジノール、メタゾシン、メタドン、メトポン、モ ルヒネ、ミロフィン、ナルビュフィン、ナルセイン、ニコモルヒネ、ノルレボル ファノール、ノルメタドン、ナロルフィン、ノルモルヒネ、ノルピパノン、オピ ウム、オキシコドン、オキシモルフォン、パパベレツム、ペンタゾシン、フェナ ドキソン、フェノモルファン、フェナゾシン、フェノペリジン、ピミノジン、ピ リトラミド、プロフェプタジン、プロメドール、プロペリジン、プロピラム、プ ロポキシフェン、スフェンタニル、トラマドール、チリジン、これらの塩および これらの混合物からなる群から選択されるオピオイド鎮痛剤である、請求の範囲 18記載の方法。 20.さらに、多重粒子の単位用量を1つのゼラチンカプセル内に含ませることを 含む、請求の範囲18記載の方法。 21.さらに、多重粒子の単位用量を1つの錠剤に圧縮することを含む、請求の範 囲18記載の方法。 22.加熱混合物を真空条件下で押し出して、実質的に非多孔質の押出し物を得る ことをさらに含む、請求の範囲18記載の方法。 23.オピオイド鎮痛剤、ならびにアルキルセルロース、アクリルおよびメタクリ ル酸ポリマーおよびコポリマー、シェラック、ゼイン、水添ヒマシ油、水添植物 油、およびこれらの混合物からなる群から選択される1以上の疎水性物質、を含 む溶融押出し配合物を、所望の治療効果を与えるのに有効な量の治療活性薬を含 有し、約8−約24時間の期間、該治療活性薬の持続放出をもたらす単位用量に分 割した、持続放出性医薬製剤。 24.オピオイド鎮痛剤がモルヒネ、コデイン、ヒドロモルホン、ヒドロコドン、 オキシコドン、オキシモルホン、ジヒドロコデイン、ジヒドロモルヒネ、トラマ ドールおよびこれらの混合物からなる群から選択される、請求の範囲23記載の押 出し物。 25.経口投与に好適な持続放出性押出し医薬品からの治療活性薬の放出特性を制 御する方法であって、 持続放出性押出し医薬品が、治療活性薬に(1)アルキルセルロース、アクリ ルおよびメタクリル酸ポリマーならびにコポリマー、シェラック、ゼイン、水添 ヒマシ油、水添植物油、ならびにこれらの混合物からなる群から選択される疎水 性物質、および(2)任意成分として、融点が30−200℃である、天然および合 成ワックス、脂肪酸、脂肪族アルコールおよびこれらの混合物からなる群から選 択される疎水性可融性担体遅延化物質を配合し、混合物を押出すのに十分な程度 軟化させるのに十分な温度に該配合物を加熱し、該加熱混合物を直径0.1−3 mm のストランドとして押し出し、該ストランドを冷却し、そして、場合によっては 、該ストランドを分割して、該押出し物の多重粒子を形成させることによって製 造されるものであり、 制御する方法が、押出し段階中に存在する空気の量を調節することによって、 押出しによって得られる押出し物の多孔度を調節することを含む方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US334,209 | 1994-11-04 | ||
US08/334,209 | 1994-11-04 | ||
US08/334,209 US5965161A (en) | 1994-11-04 | 1994-11-04 | Extruded multi-particulates |
PCT/US1995/014745 WO1996014058A1 (en) | 1994-11-04 | 1995-11-03 | Melt-extruded orally administrable opioid formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10508608A true JPH10508608A (ja) | 1998-08-25 |
JP3186064B2 JP3186064B2 (ja) | 2001-07-11 |
Family
ID=23306123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51553796A Expired - Lifetime JP3186064B2 (ja) | 1994-11-04 | 1995-11-03 | 溶融押出しによる経口投与可能なオピオイド製剤 |
Country Status (17)
Country | Link |
---|---|
US (11) | US5965161A (ja) |
EP (7) | EP0785775B2 (ja) |
JP (1) | JP3186064B2 (ja) |
KR (1) | KR100232945B1 (ja) |
AT (5) | ATE357909T1 (ja) |
AU (1) | AU705894B2 (ja) |
CA (1) | CA2204180C (ja) |
DE (5) | DE69535445T2 (ja) |
DK (5) | DK1449531T3 (ja) |
ES (5) | ES2308675T3 (ja) |
HK (3) | HK1069110A1 (ja) |
HU (1) | HUT77626A (ja) |
IL (5) | IL159766A (ja) |
PT (5) | PT1449531E (ja) |
TW (1) | TW425288B (ja) |
WO (1) | WO1996014058A1 (ja) |
ZA (1) | ZA959367B (ja) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1050306A (ja) * | 1996-07-31 | 1998-02-20 | Toyota Autom Loom Works Ltd | 水素吸蔵合金電極の製造方法 |
JP2003513032A (ja) * | 1999-10-29 | 2003-04-08 | ユーロ−セルティーク,エス.エイ. | 制御放出ヒドロコドン処方 |
JP2004528338A (ja) * | 2001-05-02 | 2004-09-16 | ユーロ−セルティーク,エス.エイ. | 一日に一回のオキシコドン製剤 |
JP2006502192A (ja) * | 2002-09-23 | 2006-01-19 | ベリオン インコーポレイテッド | 乱用抵抗性の医薬組成物 |
JP2007520429A (ja) * | 2003-06-27 | 2007-07-26 | ユーロ−セルティーク エス.エイ. | マルチ微粒子 |
JP2008504327A (ja) * | 2004-07-01 | 2008-02-14 | グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 乱用に対して保護された経口剤形 |
JP2008528654A (ja) * | 2005-02-04 | 2008-07-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 遅延放出性を有する耐破壊性の投薬形 |
JP2008231110A (ja) * | 2000-10-30 | 2008-10-02 | Euro-Celtique Sa | ヒドロコドン放出制御製剤 |
JP2009513717A (ja) * | 2005-10-31 | 2009-04-02 | アルザ・コーポレーシヨン | オピオイド徐放性経口投与製剤に対するアルコール誘発の用量ダンピングの軽減方法 |
JP2009523833A (ja) * | 2006-01-21 | 2009-06-25 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 乱用薬剤送達のための製剤および方法 |
JP2009538832A (ja) * | 2006-05-22 | 2009-11-12 | ビオヒット・ユルキネン・オサケユキテュア | 胃内でアセトアルデヒドを結合するための組成物および方法 |
JP2010100641A (ja) * | 2000-12-26 | 2010-05-06 | Lab Servier | イバブラジン制御放出のための熱成形可能な固形医薬組成物 |
JP2010519236A (ja) * | 2007-02-22 | 2010-06-03 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 胃液抵抗性の作用物質−マトリックスを有しているペレット |
JP2010529059A (ja) * | 2007-06-08 | 2010-08-26 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 味のマスキングが改善された押出物 |
JP2011510048A (ja) * | 2008-01-24 | 2011-03-31 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 低減したアルコール相互作用を有する乱用抵抗性溶融押出製剤 |
JP2012502968A (ja) * | 2008-09-18 | 2012-02-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | ポリ(ε−カプロラクトン)を含む医薬剤形 |
JP2012193186A (ja) * | 2004-02-12 | 2012-10-11 | Euro-Celtique Sa | 放出制御製剤処方物、単位用量形態、乾燥顆粒、マルチ粒子、調製方法、共重合体の使用、および製剤処方物における耐改ざん性を付与する方法 |
JP2013100306A (ja) * | 2005-01-28 | 2013-05-23 | Euro-Celtique Sa | 耐アルコール性剤形 |
JP2013537915A (ja) * | 2010-09-24 | 2013-10-07 | キューアールエックスファーマ リミテッド | オピオイドの制御放出製剤 |
JP2014532651A (ja) * | 2011-10-26 | 2014-12-08 | ケムファーム・インコーポレーテッド | ヒドロモルホンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体、そのプロドラッグ、製造法及び使用 |
JP2016504349A (ja) * | 2012-12-31 | 2016-02-12 | サムヤン バイオファーマシューティカルズ コーポレイション | 溶融押出された放出制御用薬学組成物、およびこれを含む経口用製剤 |
Families Citing this family (310)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US20020006438A1 (en) * | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
DE19531277A1 (de) * | 1995-08-25 | 1997-02-27 | Basf Ag | Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
DE19539360A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
GB9614902D0 (en) * | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
JP2002511777A (ja) * | 1996-10-28 | 2002-04-16 | ゼネラル ミルズ,インコーポレイテッド | 調放性粒子の埋包およびカプセル化 |
EP1342548B1 (en) * | 1996-10-28 | 2015-12-23 | General Mills, Inc. | Embedding and encapsulation of controlled release particles and encapsulated product |
BE1010803A3 (fr) * | 1996-12-16 | 1999-02-02 | Therabel Research Sa | Comprimes pharmaceutiques a liberation prolongee a base de tramadol et leur preparation. |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
WO1999001111A1 (en) | 1997-07-02 | 1999-01-14 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
DE19733505A1 (de) * | 1997-08-01 | 1999-02-04 | Knoll Ag | Schnell wirksames Analgeticum |
RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US6559158B1 (en) * | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
DK1041987T3 (da) | 1997-12-22 | 2006-08-21 | Euro Celtique Sa | Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon |
HUP0100310A3 (en) * | 1997-12-22 | 2002-11-28 | Euro Celtique Sa | A method of preventing abuse of opioid dosage forms |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8524277B2 (en) | 1998-03-06 | 2013-09-03 | Alza Corporation | Extended release dosage form |
US6074689A (en) * | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
DK1065936T3 (da) | 1998-03-23 | 2009-11-02 | Gen Mills Inc | Indkapsling af bestanddele i spiselige produkter |
AR018321A1 (es) * | 1998-03-26 | 2001-11-14 | Alza Corp | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
DE19859636A1 (de) * | 1998-12-23 | 2000-06-29 | Hexal Ag | Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff |
US7429407B2 (en) * | 1998-12-30 | 2008-09-30 | Aeromatic Fielder Ag | Process for coating small bodies, including tablets |
AU2963400A (en) * | 1999-01-14 | 2000-08-01 | Amcol International Corporation | Improved controlled release compositions and method |
DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
FR2795326B1 (fr) * | 1999-06-28 | 2001-08-31 | Adir | Composition pharmaceutique solide thermoformable a liberation controlee |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
DE19940944B4 (de) * | 1999-08-31 | 2006-10-12 | Grünenthal GmbH | Retardierte, orale, pharmazeutische Darreichungsformen |
DE19943501A1 (de) * | 1999-09-10 | 2001-03-15 | Basf Ag | Unterwassergranulation wirkstoffhaltiger Schmelzen |
US6500463B1 (en) | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
US6491953B1 (en) | 2000-01-07 | 2002-12-10 | Amcol International Corporation | Controlled release compositions and method |
US6953593B2 (en) * | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
RS50407B (sr) | 2000-02-08 | 2009-12-31 | Euro-Celtique S.A., | Oralne formulacije opijatnog agonista otporne na mehaničke,termičke i/ili hemijske promene fizičkih osobina doznog oblika |
AU3400501A (en) * | 2000-02-28 | 2001-09-12 | Vectura Ltd | Improvements in or relating to the delivery of oral drugs |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US6436453B1 (en) | 2000-06-16 | 2002-08-20 | General Mills, Inc. | Production of oil encapsulated minerals and vitamins in a glassy matrix |
US6468568B1 (en) | 2000-06-16 | 2002-10-22 | General Mills, Inc. | Oligosaccharide encapsulated mineral and vitamin ingredients |
FR2818550B1 (fr) * | 2000-12-26 | 2003-02-07 | Servier Lab | Composition pharmaceutique solide thermoformable pour la liberation controle de perindopril |
FR2818549B1 (fr) * | 2000-12-26 | 2003-02-07 | Servier Lab | Composition pharmaceutique solide thermoformable pour la liberation controlee de trimetazidine |
US20040172169A1 (en) * | 2001-03-02 | 2004-09-02 | Curtis Wright | Method and apparatus for compouding individualized dosege forms |
WO2002072064A2 (en) * | 2001-03-09 | 2002-09-19 | Dow Global Technologies Inc. | Granular composition comprising an active compound and a cellulose ether and the use thereof |
US7858118B2 (en) * | 2001-04-11 | 2010-12-28 | Galephar Pharmaceutical Research, Inc. | Extended release composition containing Tramadol |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
ES2361148T3 (es) | 2001-05-11 | 2011-06-14 | Endo Pharmaceuticals Inc. | Forma de dosificación de opioides de liberación controlada resistente al abuso. |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
AUPR510001A0 (en) * | 2001-05-18 | 2001-06-14 | Jupitar Pty Ltd | Formulation and method |
JP4310605B2 (ja) | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | 医薬用組成物 |
DE60234183D1 (de) * | 2001-06-05 | 2009-12-10 | Univ Chicago | Verwendung von methylnaltrexon zur behandlung von immunsuppression |
GB0113841D0 (en) * | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
WO2003002100A1 (en) * | 2001-06-26 | 2003-01-09 | Farrell John J | Tamper-proof narcotic delivery system |
EP1406630A1 (en) * | 2001-07-06 | 2004-04-14 | Endo Pharmaceuticals Inc. | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
ATE376832T1 (de) * | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | Verzögert freisetzende formulierungen von oxymorphon |
CA2454328C (en) | 2001-07-18 | 2008-03-18 | Christopher D. Breder | Pharmaceutical combinations of oxycodone and naloxone |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
MXPA04001210A (es) | 2001-08-06 | 2004-07-08 | Euro Celtique Sa | Formulaciones de agonista opioide con antagonista liberable y aislado. |
US7157103B2 (en) * | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20030091635A1 (en) * | 2001-09-26 | 2003-05-15 | Baichwal Anand R. | Opioid formulations having reduced potential for abuse |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
US7491407B2 (en) * | 2001-10-31 | 2009-02-17 | North Carolina State University | Fiber-based nano drug delivery systems (NDDS) |
HRP20020124A2 (en) * | 2002-02-11 | 2003-10-31 | Pliva D D | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
DE10208344A1 (de) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Schmelzextrusion von Wirkstoffsalzen |
CN102813654A (zh) | 2002-04-05 | 2012-12-12 | 欧洲凯尔蒂克公司 | 含有羟氢可待酮和烯丙羟吗啡酮的药物制剂 |
WO2003090717A1 (en) * | 2002-04-23 | 2003-11-06 | Nanotherapeutics, Inc | Process of forming and modifying particles and compositions produced thereby |
MXPA04012021A (es) * | 2002-05-31 | 2005-08-16 | Johnson & Johnson | Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona. |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
GB0214013D0 (en) * | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
EP1594467A4 (en) * | 2002-07-05 | 2008-10-22 | Collegium Pharmaceutical Inc | MISUSE OF PHARMACEUTICAL COMPOSITIONS OF OPIOIDES AND OTHER MEDICAMENTS |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
PT1551372T (pt) | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | Subunidade de sequestração e composições e métodos relacionados |
US20050020613A1 (en) * | 2002-09-20 | 2005-01-27 | Alpharma, Inc. | Sustained release opioid formulations and method of use |
US20090162431A1 (en) * | 2002-09-21 | 2009-06-25 | Shuyi Zhang | Sustained release formulations containing acetaminophen and tramadol |
TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
EP2218448B1 (en) | 2002-12-13 | 2015-09-23 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
DE10300325A1 (de) | 2003-01-09 | 2004-07-22 | Hexal Ag | Granulat mit öliger Substanz, Herstellungsverfahren und Tablette |
CN100500130C (zh) * | 2003-01-23 | 2009-06-17 | 株式会社太平洋 | 缓释制剂及其制备方法 |
US7136656B2 (en) * | 2003-03-20 | 2006-11-14 | Interdigital Technology Corporation | Method of fast dynamic channel allocation call admission control for radio link addition in radio resource management |
EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
JP2006522099A (ja) * | 2003-04-04 | 2006-09-28 | ファルマシア コーポレーション | 複合粒状体からなる経口徐放性圧縮錠 |
CN1767855A (zh) * | 2003-04-08 | 2006-05-03 | 普罗热尼奇制药公司 | 包含缓泻剂和外周阿片拮抗剂的便秘的组合疗法 |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
MXPA05010817A (es) | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Formulaciones farmaceuticas que contienen metilnaltrexona. |
RU2373936C2 (ru) * | 2003-04-08 | 2009-11-27 | Проджиникс Фармасьютикалз, Инк. | Применение метилналтрексона для лечения синдрома раздраженного кишечника |
EP1615625A4 (en) | 2003-04-21 | 2010-12-15 | Euro Celtique Sa | INVIOLABLE DOSAGE FORM CONTAINING CO-EXTRUDED PARTICLES OF REPELLENT AGENT AND METHOD OF MANUFACTURING THE SAME |
MY135852A (en) * | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
US20060165790A1 (en) * | 2003-06-27 | 2006-07-27 | Malcolm Walden | Multiparticulates |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
ES2289542T3 (es) * | 2003-08-06 | 2008-02-01 | Grunenthal Gmbh | Forma farmaceutica protegida contra un posible abuso. |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
US20050089558A1 (en) * | 2003-10-28 | 2005-04-28 | Alamo Pharmaceuticals, Llc | Compositions and methods for the co-formulation and administration of tramadol and propoxyphene |
WO2005053651A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
ATE399536T1 (de) | 2003-12-04 | 2008-07-15 | Pfizer Prod Inc | Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
RU2006119453A (ru) * | 2003-12-04 | 2007-12-20 | Пфайзер Продактс Инк. (Us) | Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
ES2600577T3 (es) | 2003-12-04 | 2017-02-09 | Bend Research, Inc. | Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos |
BRPI0416535A (pt) * | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo |
SI1691892T1 (sl) * | 2003-12-09 | 2007-08-31 | Euro Celtique Sa | Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave |
US8883204B2 (en) * | 2003-12-09 | 2014-11-11 | Purdue Pharma L.P. | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
GB0403100D0 (en) * | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Particulates |
GB0403098D0 (en) * | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
KR100963914B1 (ko) | 2004-03-30 | 2010-06-17 | 유로-셀띠끄 소시에떼 아노님 | 흡착제 및 억제제를 포함하는 내변조성 제형 |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1765292B1 (en) | 2004-06-12 | 2017-10-04 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
CA2572928A1 (en) * | 2004-07-22 | 2006-02-26 | Amorepacific Corporation | Sustained-release preparations containing topiramate and the producing method thereof |
GB2418854B (en) * | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
WO2006028830A2 (en) * | 2004-09-01 | 2006-03-16 | Euro-Celtique S.A. | Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax |
TWI369203B (en) | 2004-11-22 | 2012-08-01 | Euro Celtique Sa | Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol |
RU2401125C2 (ru) | 2004-12-27 | 2010-10-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ стабилизации лекарственного средства против деменции |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
TWI432196B (zh) * | 2005-01-18 | 2014-04-01 | Euro Celtique Sa | 內臟痛的治療 |
WO2006078842A1 (en) * | 2005-01-20 | 2006-07-27 | Progenics Pharmaceuticals, Inc. | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
MX2007009162A (es) * | 2005-01-28 | 2007-10-23 | Euro Celtique Sa | Formas de dosis rsistente al alcohol. |
DE102005005449A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
ES2714198T3 (es) | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
JP5597343B2 (ja) * | 2005-04-28 | 2014-10-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬を含有する組成物 |
GB0509276D0 (en) * | 2005-05-06 | 2005-06-15 | Univ Cranfield | Synthetic receptor |
CN102552162A (zh) * | 2005-05-10 | 2012-07-11 | 诺瓦提斯公司 | 制备含有可压性差的治疗性化合物的组合物的挤压方法 |
CN101166517B (zh) * | 2005-05-10 | 2012-01-04 | 诺瓦提斯公司 | 制备含有可压性差的治疗性化合物的组合物的挤压方法 |
AU2011224098B2 (en) * | 2005-05-10 | 2013-10-31 | Novartis Ag | Extrusion process for making compositions with poorly compressible therapeutic compounds |
US20060286148A1 (en) * | 2005-05-18 | 2006-12-21 | Ppd, Inc. | Method of forming implants |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
JP2008542419A (ja) * | 2005-06-09 | 2008-11-27 | ユーロ−セルティーク エス.エイ. | 神経刺激性ステロイドの医薬組成物及びその使用 |
TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
CA2578626C (en) | 2005-06-27 | 2011-07-19 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
PL2402005T3 (pl) | 2005-08-24 | 2021-11-22 | Endo Pharmaceuticals Inc. | Formulacje nalbufiny o przedłużonym uwalnianiu |
US8394812B2 (en) | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
US8795723B2 (en) | 2005-09-09 | 2014-08-05 | Angelini Pharma Inc. | Sustained drug release compositions |
PT1928427E (pt) * | 2005-09-23 | 2010-03-01 | Hoffmann La Roche | Nova forma galénica |
KR100656019B1 (ko) * | 2005-10-20 | 2006-12-08 | 현대자동차주식회사 | 신규의 폴리이미드-폴리벤지이미다졸의 공중합체와, 이를이용한 고분자 전해질 막 |
US20070160960A1 (en) * | 2005-10-21 | 2007-07-12 | Laser Shot, Inc. | System and method for calculating a projectile impact coordinates |
CN1957909B (zh) * | 2005-10-31 | 2013-09-11 | 阿尔扎公司 | 降低鸦片样物质持续释放口服剂型的由醇诱导的剂量突然释放的方法 |
EP1849460A3 (en) * | 2005-10-31 | 2007-11-14 | ALZA Corporation | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms |
US7803413B2 (en) | 2005-10-31 | 2010-09-28 | General Mills Ip Holdings Ii, Llc. | Encapsulation of readily oxidizable components |
US20090082466A1 (en) * | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
WO2007056142A2 (en) * | 2005-11-02 | 2007-05-18 | Theraquest Biosciences, Llc | Methods of preventing the serotonin syndrome and compositions for use therefor |
US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
US8329744B2 (en) | 2005-11-02 | 2012-12-11 | Relmada Therapeutics, Inc. | Methods of preventing the serotonin syndrome and compositions for use thereof |
US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
EP1810678A1 (de) | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution |
US20090022798A1 (en) * | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
US20090317355A1 (en) * | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
US20100172989A1 (en) * | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
EP1859788A1 (en) * | 2006-05-24 | 2007-11-28 | Abbott GmbH & Co. KG | Production of enveloped pharmaceutical dosage forms |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
EP2526932B1 (en) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmaceutical composition |
WO2008011595A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
US8128460B2 (en) * | 2006-09-14 | 2012-03-06 | The Material Works, Ltd. | Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
US8653066B2 (en) | 2006-10-09 | 2014-02-18 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
DE102007009243A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
GB2447898B (en) * | 2007-03-24 | 2011-08-17 | Reckitt Benckiser Healthcare | A tablet having improved stability with at least two actives |
PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
US20100305323A1 (en) | 2007-03-29 | 2010-12-02 | Smolenskaya Valeriya N | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
JP5461386B2 (ja) | 2007-03-29 | 2014-04-02 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | 末梢オピオイド受容体アンタゴニストおよびその使用 |
DE102007025858A1 (de) | 2007-06-01 | 2008-12-04 | Grünenthal GmbH | Verfahren zur Herstellung einer Arzneimitteldarreichungsform |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
MX2010002409A (es) | 2007-09-03 | 2010-05-19 | Nanotherapeutics Inc | Composiciones y metodos para la distribucion de farmacos escasamente solubles. |
ES2406939T3 (es) † | 2007-10-19 | 2013-06-10 | Otsuka Pharmaceutical Co., Ltd. | Preparación farmacéutica de matriz sólida |
US8415401B2 (en) | 2007-12-06 | 2013-04-09 | Durect Corporation | Oral pharmaceutical dosage forms |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
EP2224808A4 (en) * | 2007-12-17 | 2013-11-27 | Alpharma Pharmaceuticals Llc | PHARMACEUTICAL COMPOSITION |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
US20090246276A1 (en) * | 2008-01-28 | 2009-10-01 | Graham Jackson | Pharmaceutical Compositions |
EP2240489A1 (en) | 2008-02-06 | 2010-10-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
AU2009223061B2 (en) | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
MX2010011962A (es) * | 2008-04-30 | 2010-11-30 | Novartis Ag | Proceso continuo para hacer composiciones farmaceuticas. |
BRPI0912014A2 (pt) | 2008-05-09 | 2019-03-06 | Grünenthal GmbH | processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização |
ES2393949T3 (es) * | 2008-07-03 | 2013-01-02 | Novartis Ag | Proceso de granulación en estado fundido |
US20110177133A1 (en) * | 2008-07-07 | 2011-07-21 | Michael Hopp | Use of opioid antagonists for treating urinary retention |
CA2734646C (en) | 2008-08-20 | 2016-06-28 | James W. Mcginity | Hot-melt extrusion of modified release multi-particulates |
US10668012B2 (en) | 2008-09-04 | 2020-06-02 | Farnam Companies, Inc. | Chewable sustained release formulations |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
CA2750144C (en) | 2008-12-31 | 2016-10-25 | Upsher-Smith Laboratories, Inc. | Opioid-containing oral pharmaceutical compositions and methods |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
WO2010103039A1 (en) | 2009-03-10 | 2010-09-16 | Euro-Celtique S.A. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
GB0909680D0 (en) * | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
US9743228B2 (en) | 2009-06-22 | 2017-08-22 | Qualcomm Incorporated | Transport of LCS-related messages for LTE access |
CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
RU2015138422A (ru) | 2009-07-22 | 2018-12-25 | Грюненталь Гмбх | Стабильная при окислении, прочная на излом лекарственная форма |
BR112012004525A2 (pt) * | 2009-08-31 | 2016-03-22 | Depomed Inc | composição farmacêuticas gástrico-rententivas para liberação imediata ou prolongada de acetaminofeno |
WO2011034554A1 (en) | 2009-09-17 | 2011-03-24 | Upsher-Smith Laboratories, Inc. | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9579285B2 (en) * | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
AU2011252040C1 (en) | 2010-05-10 | 2015-04-02 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
CN103002881B (zh) | 2010-05-10 | 2015-09-02 | 欧洲凯尔特公司 | 载有活性剂的颗粒与额外活性剂的组合 |
CH705273B1 (de) | 2010-05-10 | 2016-06-15 | Euro Celtique Sa | Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon. |
MX2012012991A (es) | 2010-05-11 | 2012-11-30 | Cima Labs Inc | Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol. |
PL2611426T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie |
WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
GB201020895D0 (en) * | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
CA2991217C (en) | 2010-12-22 | 2020-06-09 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
JP5638151B2 (ja) | 2010-12-23 | 2014-12-10 | パーデュー、ファーマ、リミテッド、パートナーシップ | 不正加工抵抗性の(tamperresistant)固形経口剤形 |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
AT511581A1 (de) | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | Orale retardierende formulierung |
US8758826B2 (en) * | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
EP2736497B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
AU2012310250B2 (en) * | 2011-09-16 | 2016-03-03 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
AU2013203493B2 (en) * | 2012-03-02 | 2016-02-04 | Rhodes Pharmaceuticals L.P. | Tamper resistant immediate release formulations |
TWI522101B (zh) | 2012-04-17 | 2016-02-21 | 普渡製藥有限合夥事業 | 處理由類鴉片引起之不利的藥效動力反應之系統和方法 |
MX362357B (es) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis. |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
EP2877161A1 (en) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
BR112015000320B1 (pt) | 2012-07-12 | 2023-03-07 | SpecGx LLC | Composições farmacêuticas dissuasivas de abuso e seu processo de preparação |
US10702453B2 (en) | 2012-11-14 | 2020-07-07 | Xerox Corporation | Method and system for printing personalized medication |
WO2014102745A1 (en) * | 2012-12-31 | 2014-07-03 | Aizant Drug Research Solutions Private Limited | High drug load ibuprofen sustained release composition |
BR112015017451B1 (pt) | 2013-02-05 | 2023-01-10 | Purdue Pharma L.P. | Formulações farmacêuticas resistentes à violação |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9572885B2 (en) | 2013-03-15 | 2017-02-21 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
AR096439A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido que contiene una o más partículas |
WO2014191397A1 (en) | 2013-05-29 | 2014-12-04 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
CA2918004C (en) | 2013-07-23 | 2018-11-20 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
UA116405C2 (uk) | 2013-11-13 | 2018-03-12 | Євро-Селтік С.А. | Гідроморфон та налоксон для лікування болю та синдрому опіоїдної дисфункції кишечнику |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
JP2017518980A (ja) | 2014-05-12 | 2017-07-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールを含む、改変防止即時放出カプセル製剤 |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
CH710097A2 (de) | 2014-09-12 | 2016-03-15 | Chemspeed Technologies Ag | Verfahren und Vorrichtung zur Herstellung eines Extrudats. |
EP3718404A1 (en) | 2014-10-17 | 2020-10-07 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progession |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
CA2969221C (en) | 2014-12-02 | 2021-01-12 | Travis Mickle | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
CA3055170A1 (en) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
BR112018069785A2 (pt) | 2016-03-31 | 2019-01-29 | SpecGx LLC | formas de dosagem dissuasivas de abuso de liberação prolongada |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
JP2020503269A (ja) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | 経口ウンデカン酸テストステロン療法 |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
EP3703724A1 (en) | 2017-11-02 | 2020-09-09 | NatureCeuticals Sdn. Bhd. | Extract of orthosiphon stamineus, formulations, and uses thereof |
EP3965733A4 (en) | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE |
CN110755396B (zh) * | 2019-12-06 | 2022-04-08 | 北京悦康科创医药科技股份有限公司 | 一种布洛芬缓释小丸及其制备方法 |
CN115209876A (zh) * | 2020-03-11 | 2022-10-18 | 泽井制药株式会社 | 颗粒和使用该颗粒的制剂 |
CN113080436B (zh) * | 2021-04-08 | 2024-03-01 | 南京纽邦生物科技有限公司 | γ-氨基丁酸干混悬剂及其制备方法 |
Family Cites Families (222)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US33093A (en) * | 1861-08-20 | Improvement in potato-diggers | ||
US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
US2743303A (en) * | 1955-04-01 | 1956-04-24 | Du Pont | Process for the preparation of 1, 1, 4, 4-tetrafluorobutadiene 1, 3 from acetylene and tetrafluoroethylene |
US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
US4132753A (en) * | 1965-02-12 | 1979-01-02 | American Cyanamid Company | Process for preparing oral sustained release granules |
US3830934A (en) * | 1967-07-27 | 1974-08-20 | Gruenenthal Chemie | Analgesic and antitussive compositions and methods |
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US3714350A (en) * | 1969-03-10 | 1973-01-30 | Mobil Oil Corp | Phosphoryl and thiophosphoryl pyrones as insecticides |
US4344431A (en) * | 1969-03-24 | 1982-08-17 | University Of Delaware | Polymeric article for dispensing drugs |
US3880991A (en) * | 1969-03-24 | 1975-04-29 | Brook David E | Polymeric article for dispensing drugs |
GB1357737A (en) * | 1970-10-09 | 1974-06-26 | Arpic Sa | Sustained release pharmaceutical compositions |
GB1405088A (en) | 1971-06-03 | 1975-09-03 | Mundipharma Ag | Slow release formulation |
FR2183546B1 (ja) * | 1972-05-10 | 1975-06-20 | Servier Lab | |
US3965256A (en) * | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4450150A (en) * | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
DE2360796B2 (de) * | 1973-12-06 | 1977-06-02 | Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm |
US3974157A (en) * | 1974-03-04 | 1976-08-10 | Pennwalt Corporation | 1-(Amino-alkyl)-2-aryl-cyclohexane alcohols and esters |
DE2426812A1 (de) | 1974-06-04 | 1976-01-02 | Klinge Co Chem Pharm Fab | Verfahren zur herstellung von granulaten |
DE2426811A1 (de) | 1974-06-04 | 1976-01-08 | Klinge Co Chem Pharm Fab | Verfahren zur herstellung von retard-tabletten |
DE2439538C3 (de) | 1974-08-17 | 1980-07-17 | Ludwig Heumann & Co Gmbh, 8500 Nuernberg | Verfahren zur Herstellung von oral zu verabreichenden Arzneimitteln mit verzögerter Wirkungsfreigabe |
US4076798A (en) * | 1975-05-29 | 1978-02-28 | American Cyanamid Company | High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition |
GB1504553A (en) | 1975-11-17 | 1978-03-22 | Sandoz Ltd | Tablet formulations |
GB1593261A (en) * | 1976-07-23 | 1981-07-15 | Inveresk Res Int | Controlled release suppository |
US4406883A (en) * | 1976-07-23 | 1983-09-27 | Merrell Dow Pharmaceuticals Inc. | Controlled release suppositories consisting essentially of a linear polymer particularly, polyvinyl pyrrolidones |
US4173417A (en) * | 1977-04-15 | 1979-11-06 | Hpm Corporation | Extrusion apparatus and method |
US4366172A (en) * | 1977-09-29 | 1982-12-28 | The Upjohn Company | 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use |
US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
EP0008083A1 (de) * | 1978-08-15 | 1980-02-20 | Ciba-Geigy Ag | Verfahren zur Herstellung von Granulaten schwerschmelzbarer Zusatzstoffe für Kunststoffe, insbesondere von Pigmenten, durch thermische Rollgranulierung und die so erhaltenen Granulate |
CH637014A5 (de) | 1978-09-29 | 1983-07-15 | Sandoz Ag | Verfahren zur herstellung von suppositorien. |
DE2923279B1 (de) | 1979-06-08 | 1980-11-20 | Kali Chemie Pharma Gmbh | Verfahren zur Herstellung von Pankreatin-Pellets |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
JPS56140915A (en) * | 1980-04-07 | 1981-11-04 | Yamanouchi Pharmaceut Co Ltd | Pharmaceutical preparation for solid drug |
DE3024416C2 (de) * | 1980-06-28 | 1982-04-15 | Gödecke AG, 1000 Berlin | Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung |
US4346709A (en) * | 1980-11-10 | 1982-08-31 | Alza Corporation | Drug delivery devices comprising erodible polymer and erosion rate modifier |
JPS57171428A (en) * | 1981-04-13 | 1982-10-22 | Sankyo Co Ltd | Preparation of coated solid preparation |
DE3124983A1 (de) | 1981-06-25 | 1983-01-20 | Meditest Inst Fuer Medizinisch | Arzneiformen zur oralen verabreichung |
US4374082A (en) * | 1981-08-18 | 1983-02-15 | Richard Hochschild | Method for making a pharmaceutical and/or nutritional dosage form |
US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4421736A (en) * | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
AU1873783A (en) | 1982-10-08 | 1984-04-12 | Verex Laboratories Inc. | Constant release formulation |
US4469613A (en) * | 1983-02-23 | 1984-09-04 | International Flavors & Fragrances Inc. | Detergent bar containing poly(epsilon caprolactone) and aromatizing agent |
US4882167A (en) * | 1983-05-31 | 1989-11-21 | Jang Choong Gook | Dry direct compression compositions for controlled release dosage forms |
JPS6013838A (ja) * | 1983-07-04 | 1985-01-24 | Mitsui Petrochem Ind Ltd | ポリプロピレン組成物 |
US4917899A (en) * | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
EP0147780A3 (en) | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
EP0152379A3 (de) | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen |
GB8405112D0 (en) * | 1984-02-28 | 1984-04-04 | Akzo Nv | Anti-arrhythmic amino-alcohols |
US4649042A (en) * | 1984-05-31 | 1987-03-10 | Eli Lilly And Company | Rumen delivery device |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US4894234A (en) * | 1984-10-05 | 1990-01-16 | Sharma Shri C | Novel drug delivery system for antiarrhythmics |
EP0189861A3 (en) | 1985-01-26 | 1988-02-17 | Showa Denko Kabushiki Kaisha | Percutaneous absorption accelerator for ionic water-soluble medicine |
US4772475A (en) | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
US4720384A (en) * | 1985-05-03 | 1988-01-19 | E. I. Du Pont De Nemours And Company | Manufacture of hollow fine tubular drug delivery systems |
FR2581541B1 (fr) * | 1985-05-09 | 1988-05-20 | Rhone Poulenc Sante | Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
JPS61293911A (ja) * | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | 徐放化製剤 |
DE3524003A1 (de) * | 1985-07-04 | 1987-01-08 | Heumann Ludwig & Co Gmbh | Arzneimittelgranulat mit verzoegerter wirkstofffreisetzung und verfahren zu seiner herstellung |
FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
GB8521350D0 (en) * | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
EP0223431B1 (en) * | 1985-11-08 | 1992-04-29 | Imperial Chemical Industries Plc | Apparatus and method for forming pellets |
US4882159A (en) * | 1985-12-20 | 1989-11-21 | Warner Lambert Co. | Confectionery delivery system for appetite suppressants |
US4882157A (en) * | 1985-12-20 | 1989-11-21 | Yang Robert K | Confectionery delivery system for anti-cholesterolemics |
US4882156A (en) * | 1985-12-20 | 1989-11-21 | Warner Lambert Co. | Confectionery delivery system for expectorants |
US4882151A (en) * | 1985-12-20 | 1989-11-21 | Warner Lambert Co. | Confectionery delivery system for antihistimines |
US4879108A (en) * | 1985-12-20 | 1989-11-07 | Warner-Lambert Company | Confectionery delivery system for antipyretics |
US4882155A (en) * | 1985-12-20 | 1989-11-21 | Warner Lambert Co. | Confectionery delivery system for antiarrhythmics |
US4778676A (en) * | 1985-12-20 | 1988-10-18 | Warner-Lambert Company | Confectionery delivery system for actives |
US4882152A (en) * | 1985-12-20 | 1989-11-21 | Yang Robert K | Confectionery delivery system for laxatives, vitamins and antacids |
US4882153A (en) * | 1985-12-20 | 1989-11-21 | Warner Lambert Co. | Confectionery delivery system for antitussives |
JP2521504B2 (ja) | 1985-12-27 | 1996-08-07 | 昭和電工株式会社 | 酵素の造粒法 |
DE3602370A1 (de) | 1986-01-27 | 1987-08-06 | Chrubasik Sigrun | Verwendung von analgetica durch inhalation |
DE3602360A1 (de) | 1986-01-27 | 1987-07-30 | Krupp Polysius Ag | Seitenkratzer fuer schuettguthalde |
US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
GB2186485B (en) * | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
US4994227A (en) * | 1986-03-10 | 1991-02-19 | American Cyanamid Company | Method for the preparation of sustained released bolus formulation |
DE3610878A1 (de) | 1986-04-01 | 1987-10-08 | Boehringer Ingelheim Kg | Formlinge aus pellets |
DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
DE3612211A1 (de) † | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
US4820523A (en) | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
ES2058111T3 (es) * | 1986-06-10 | 1994-11-01 | Euro Celtique Sa | Composicion de liberacion controlada de dihidrocodeina. |
USRE33093E (en) | 1986-06-16 | 1989-10-17 | Johnson & Johnson Consumer Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
DE3623193A1 (de) | 1986-07-10 | 1988-01-14 | Gruenenthal Gmbh | Neue verbindungen, diese enthaltende arzneimittel und verfahren zu deren herstellung |
US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4970075A (en) * | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
JPH0816066B2 (ja) | 1986-07-18 | 1996-02-21 | エーザイ株式会社 | 持続性薬効製剤 |
US4760094A (en) | 1986-10-21 | 1988-07-26 | American Home Products Corporation (Del.) | Spray dried acetaminophen |
GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
IE873172L (en) | 1986-12-29 | 1988-06-29 | Harvard College | Continuous process for producing a comestible tablet |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
ZA882783B (en) | 1987-06-10 | 1988-10-20 | Warner-Lambert Company | Process for preparing a pharmaceutical composition |
DE3721721C1 (de) * | 1987-07-01 | 1988-06-09 | Hoechst Ag | Verfahren zur Umhuellung von Granulaten |
GB8717168D0 (en) | 1987-07-21 | 1987-08-26 | Roussel Lab Ltd | Controlled-release device |
FR2618329B1 (fr) | 1987-07-22 | 1997-03-28 | Dow Corning Sa | Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede |
US5049394A (en) * | 1987-09-11 | 1991-09-17 | E. R. Squibb & Sons, Inc. | Pharmaceutical composition containing high drug load and method for preparing same |
US4959208A (en) * | 1987-10-19 | 1990-09-25 | Ppg Industries, Inc. | Active agent delivery device |
US5418154A (en) * | 1987-11-17 | 1995-05-23 | Brown University Research Foundation | Method of preparing elongated seamless capsules containing biological material |
SE463450B (sv) | 1987-12-11 | 1990-11-26 | Nemo Ivarson | Anordning foer blandning, knaadning och extrudering av produkter framstaellda av vaetska och pulver |
EP0327295A3 (en) | 1988-02-01 | 1989-09-06 | F.H. FAULDING & CO. LTD. | Tetracycline dosage form |
US4842761A (en) * | 1988-03-23 | 1989-06-27 | International Flavors & Fragrances, Inc. | Compositions and methods for controlled release of fragrance-bearing substances |
DE3812567A1 (de) | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
US5472710A (en) | 1988-04-16 | 1995-12-05 | Schwarz Pharma Ag | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture |
DE3812799A1 (de) | 1988-04-16 | 1989-10-26 | Sanol Arznei Schwarz Gmbh | Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung |
JP2681373B2 (ja) * | 1988-07-18 | 1997-11-26 | 塩野義製薬株式会社 | 徐放性製剤の製造法 |
DE3827061C1 (ja) | 1988-08-10 | 1990-02-15 | Deutsche Gelatine-Fabriken Stoess & Co Gmbh, 6930 Eberbach, De | |
US4925675A (en) * | 1988-08-19 | 1990-05-15 | Himedics, Inc. | Erythromycin microencapsulated granules |
GB8820327D0 (en) | 1988-08-26 | 1988-09-28 | May & Baker Ltd | New compositions of matter |
DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
DE3830355A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur herstellung von pharmazeutischen tabletten |
EP0361910B1 (en) | 1988-09-30 | 1994-06-29 | Rhone-Poulenc Rorer Limited | Granular pharmaceutical formulations |
US5178868A (en) * | 1988-10-26 | 1993-01-12 | Kabi Pharmacia Aktiebolaq | Dosage form |
NZ231281A (en) | 1988-11-08 | 1991-01-29 | Takeda Chemical Industries Ltd | Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol |
JP2893191B2 (ja) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
IL92343A0 (en) | 1988-12-20 | 1990-07-26 | Gist Brocades Nv | Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them |
US5055307A (en) * | 1988-12-29 | 1991-10-08 | Asahi Kagaku Kogyo Kabushiki Kaisha | Slow release drug delivery granules and process for production thereof |
US5330766A (en) * | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
CA2007181C (en) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
CA2007055A1 (en) | 1989-01-06 | 1990-07-06 | Garth Boehm | Theophylline dosage form |
US5196203A (en) * | 1989-01-06 | 1993-03-23 | F. H. Faulding & Co. Limited | Theophylline dosage form |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5013306A (en) * | 1989-01-18 | 1991-05-07 | Becton, Dickinson And Company | Anti-infective and antithrombogenic medical articles and method for their preparation |
US5165952A (en) | 1989-01-18 | 1992-11-24 | Becton, Dickinson And Company | Anti-infective and antithrombogenic medical articles and method for their preparation |
FR2642420B1 (fr) | 1989-01-27 | 1991-09-06 | Valpan Sa Labo Pharma | Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5229148A (en) * | 1989-04-19 | 1993-07-20 | Wm. Wrigley Jr. Company | Method of combining active ingredients with polyvinyl acetates |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US4967486A (en) * | 1989-06-19 | 1990-11-06 | Glatt Gmbh | Microwave assisted fluidized bed processor |
DK161743C (da) * | 1989-07-03 | 1992-02-17 | Niro Atomizer As | Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale |
EP0415693A1 (en) | 1989-08-28 | 1991-03-06 | Arizona Technology Development Corporation | Composition and method for selective enhancement of opiate activity and reduction of opiate tolerance and dependence |
EP0418596A3 (en) * | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
US5169645A (en) * | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
IL96311A (en) | 1989-12-01 | 1995-05-26 | Abbott Lab | Medications with delayed release |
DE4000571C1 (ja) | 1990-01-10 | 1991-06-06 | Herbert 7853 Steinen De Huettlin | |
US5296266A (en) | 1990-02-22 | 1994-03-22 | Seiko Epson Corporation | Method of preparing microcapsule |
ATE145131T1 (de) | 1990-04-12 | 1996-11-15 | Shionogi & Co | Ueberzogene zusammensetzung sowie verfahren zu ihrer herstellung |
KR950005865B1 (ko) * | 1990-04-23 | 1995-06-02 | 데이진 가부시끼가이샤 | 첩부제 |
IE65045B1 (en) | 1990-04-28 | 1995-10-04 | Takeda Chemical Industries Ltd | Granulated preparations and method of producing the same |
AU643528B2 (en) | 1990-06-25 | 1993-11-18 | Mitsubishi Shoji Foodtech Co., Ltd. | Molasses-containing maltitol crystal and production thereof |
US5183690A (en) * | 1990-06-25 | 1993-02-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Starch encapsulation of biologically active agents by a continuous process |
HU208495B (en) | 1990-06-27 | 1993-11-29 | Alkaloida Vegyeszeti Gyar | Process for producing retarde pharmaceutical compositions |
FR2663818B1 (fr) | 1990-06-29 | 1993-07-09 | Rhone Poulenc Nutrition Animale | Procede de preparation de granules de principes actifs par extrusion. |
GB2246514B (en) | 1990-08-01 | 1993-12-15 | Scras | Sustained release pharmaceutical compositions and the preparation of particles for use therein |
US5035509A (en) * | 1990-08-13 | 1991-07-30 | Hpm Corporation | Multi-channel extrusion screw with a zig-zag undercut barrier |
ATE123237T1 (de) | 1990-08-24 | 1995-06-15 | Spirig Ag | Verfahren zur herstellung von pellets. |
JP2875611B2 (ja) * | 1990-08-29 | 1999-03-31 | エーザイ株式会社 | ケイ酸カルシウム含有外用剤 |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
DE4031881C2 (de) | 1990-10-08 | 1994-02-24 | Sanol Arznei Schwarz Gmbh | Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung |
GB2248842A (en) | 1990-10-16 | 1992-04-22 | American Cyanamid Co | Film-forming polymer compositions |
SE9003296L (sv) * | 1990-10-16 | 1992-04-17 | Kabi Pharmacia Ab | Foerfarande foer att formulera laekemedel |
US5271934A (en) * | 1990-10-22 | 1993-12-21 | Revlon Consumer Products Corporation | Encapsulated antiperspirant salts and deodorant/antiperspirants |
FR2670398B1 (fr) | 1990-12-14 | 1995-02-17 | Roquette Freres | Composition pulverulente directement compressible et procede d'obtention. |
US5240400A (en) * | 1990-12-17 | 1993-08-31 | Fuji Paudal Kabushiki Kaisha | Screw-type extrusion granulating apparatus, especially for producing very fine granules |
JPH0622669B2 (ja) | 1990-12-17 | 1994-03-30 | 不二パウダル株式会社 | 前押出式スクリュー型押出し造粒機 |
US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
US5273758A (en) * | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
US5132142A (en) * | 1991-03-19 | 1992-07-21 | Glatt Gmbh | Apparatus and method for producing pellets by layering power onto particles |
IT1245891B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. |
ATE159426T1 (de) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
TW209174B (ja) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
US5380535A (en) | 1991-05-28 | 1995-01-10 | Geyer; Robert P. | Chewable drug-delivery compositions and methods for preparing the same |
DK116591D0 (da) * | 1991-06-17 | 1991-06-17 | Ferring Farma Lab | Fremgangsmaade til fremstilling af suppositorier ved komprimering og suppositorier opnaaet ved fremgangsmaaden |
DE4120760A1 (de) * | 1991-06-24 | 1993-03-04 | 3 M Medica Gmbh | Traegersysteme fuer arzneimittel |
US5330768A (en) * | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
IT1251153B (it) | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
DE4127665A1 (de) | 1991-08-22 | 1993-02-25 | Beiersdorf Ag | Galenische matrix |
US5340581A (en) | 1991-08-23 | 1994-08-23 | Gillette Canada, Inc. | Sustained-release matrices for dental application |
ATE145330T1 (de) | 1991-09-06 | 1996-12-15 | Mcneilab Inc | Zusammensetzungen, die tramadol und irgendein kodein, oxykoden oder hydrokoden enthalten, und deren verwendung |
DK0566709T5 (da) * | 1991-09-06 | 2009-05-18 | Ortho Mcneil Janssen Pharm | Præparat indeholdende et tramadolmateriale og acetaminophen og anvendelse deraf |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
GB9121204D0 (en) | 1991-10-04 | 1991-11-20 | Euro Celtique Sa | Medicament |
US5288502A (en) * | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
WO1993007859A1 (en) * | 1991-10-23 | 1993-04-29 | Warner-Lambert Company | Novel pharmaceutical pellets and process for their production |
AU661723B2 (en) | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
DE4138513A1 (de) | 1991-11-23 | 1993-05-27 | Basf Ag | Feste pharmazeutische retardform |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
EP0615438B1 (en) | 1991-12-05 | 1996-07-24 | Mallinckrodt Veterinary, Inc. | A carbohydrate glass matrix for the sustained release of a therapeutic agent |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
GB2284760B (en) | 1993-11-23 | 1998-06-24 | Euro Celtique Sa | A method of preparing pharmaceutical compositions by melt pelletisation |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
GB2281204A (en) | 1993-07-27 | 1995-03-01 | Euro Celtique Sa | Sustained release morphine compositions |
US5167964A (en) * | 1992-02-14 | 1992-12-01 | Warner-Lambert Company | Semi-enteric drug delivery systems and methods for preparing same |
GB9203689D0 (en) * | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
JP3623805B2 (ja) * | 1992-02-20 | 2005-02-23 | ユーロセルテイツク・エス・アー | ヒドロモルホンスフェロイド調整放出製剤 |
ZA932272B (en) * | 1992-03-30 | 1993-10-19 | Alza Corp | Viscous suspensions of controlled-release drug particles |
US5262172A (en) | 1992-06-19 | 1993-11-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing buffered bile acids |
US5234697A (en) * | 1992-06-22 | 1993-08-10 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing salts of bile acids |
US5350584A (en) | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
US5429825A (en) | 1992-06-26 | 1995-07-04 | Mcneil-Ppc, Inc. | Rotomelt granulation |
DE4227385A1 (de) | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | Pankreatinmikropellets |
ES2180548T3 (es) | 1992-10-16 | 2003-02-16 | Nippon Shinyaku Co Ltd | Metodo de obtencion de matrices de cera. |
DE4236408A1 (de) | 1992-10-28 | 1994-05-05 | Siemens Ag | Schaltbare Dämpfungsvorrichtung |
DE4236752A1 (de) | 1992-10-30 | 1994-05-05 | Asta Medica Ag | Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
IT1265074B1 (it) | 1993-05-18 | 1996-10-30 | Istituto Biochimico Italiano | Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare |
IL109944A (en) | 1993-07-01 | 1998-12-06 | Euro Celtique Sa | Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
DE4325465B4 (de) * | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
EP1442745A1 (en) † | 1993-10-07 | 2004-08-04 | Euro-Celtique | Orally administrable opioid formulations having extended duration of effect |
US5476528A (en) | 1993-12-20 | 1995-12-19 | Tennessee Valley Authority | System for improving material release profiles |
JP3224931B2 (ja) | 1994-01-12 | 2001-11-05 | 株式会社日本製鋼所 | 二軸混練押出機 |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
DE4413350A1 (de) † | 1994-04-18 | 1995-10-19 | Basf Ag | Retard-Matrixpellets und Verfahren zu ihrer Herstellung |
DE4418837A1 (de) | 1994-05-30 | 1995-12-07 | Bayer Ag | Thermisches Granulierverfahren |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US6706284B2 (en) * | 2001-03-15 | 2004-03-16 | Yamanouchi Pharmaceutical Co., Ltd. | Bitterness-reduced oral pharmaceutical composition |
MXPA04001210A (es) * | 2001-08-06 | 2004-07-08 | Euro Celtique Sa | Formulaciones de agonista opioide con antagonista liberable y aislado. |
-
1994
- 1994-11-04 US US08/334,209 patent/US5965161A/en not_active Expired - Lifetime
-
1995
- 1995-11-03 DK DK04012331T patent/DK1449531T3/da active
- 1995-11-03 IL IL159766A patent/IL159766A/en not_active IP Right Cessation
- 1995-11-03 DK DK95939928.8T patent/DK0785775T4/da active
- 1995-11-03 CA CA002204180A patent/CA2204180C/en not_active Expired - Lifetime
- 1995-11-03 AT AT04012331T patent/ATE357909T1/de not_active IP Right Cessation
- 1995-11-03 DE DE69535445T patent/DE69535445T2/de not_active Expired - Lifetime
- 1995-11-03 PT PT04012331T patent/PT1449531E/pt unknown
- 1995-11-03 EP EP95939928A patent/EP0785775B2/en not_active Expired - Lifetime
- 1995-11-03 DE DE69535426T patent/DE69535426T2/de not_active Expired - Lifetime
- 1995-11-03 DK DK03015267.2T patent/DK1348429T3/da active
- 1995-11-03 DK DK04012330T patent/DK1449530T3/da active
- 1995-11-03 EP EP03015267A patent/EP1348429B1/en not_active Expired - Lifetime
- 1995-11-03 JP JP51553796A patent/JP3186064B2/ja not_active Expired - Lifetime
- 1995-11-03 EP EP04022651A patent/EP1488786A1/en not_active Ceased
- 1995-11-03 AT AT04012330T patent/ATE356616T1/de not_active IP Right Cessation
- 1995-11-03 EP EP04012331A patent/EP1449531B1/en not_active Expired - Lifetime
- 1995-11-03 PT PT06123277T patent/PT1741426E/pt unknown
- 1995-11-03 EP EP06123277A patent/EP1741426B1/en not_active Expired - Lifetime
- 1995-11-03 ES ES06123277T patent/ES2308675T3/es not_active Expired - Lifetime
- 1995-11-03 DE DE69536035T patent/DE69536035D1/de not_active Expired - Lifetime
- 1995-11-03 AU AU41570/96A patent/AU705894B2/en not_active Expired
- 1995-11-03 DK DK06123277T patent/DK1741426T3/da active
- 1995-11-03 PT PT95939928T patent/PT785775E/pt unknown
- 1995-11-03 ES ES04012330T patent/ES2282756T3/es not_active Expired - Lifetime
- 1995-11-03 IL IL12941095A patent/IL129410A/xx not_active IP Right Cessation
- 1995-11-03 HU HU9800457A patent/HUT77626A/hu active IP Right Revival
- 1995-11-03 PT PT04012330T patent/PT1449530E/pt unknown
- 1995-11-03 IL IL11587195A patent/IL115871A/xx not_active IP Right Cessation
- 1995-11-03 EP EP04012330A patent/EP1449530B1/en not_active Expired - Lifetime
- 1995-11-03 AT AT95939928T patent/ATE257375T1/de active
- 1995-11-03 WO PCT/US1995/014745 patent/WO1996014058A1/en active IP Right Grant
- 1995-11-03 KR KR1019970702984A patent/KR100232945B1/ko not_active IP Right Cessation
- 1995-11-03 PT PT03015267T patent/PT1348429E/pt unknown
- 1995-11-03 ES ES03015267T patent/ES2338641T3/es not_active Expired - Lifetime
- 1995-11-03 AT AT03015267T patent/ATE452627T1/de not_active IP Right Cessation
- 1995-11-03 DE DE69535767T patent/DE69535767D1/de not_active Expired - Lifetime
- 1995-11-03 EP EP10177509A patent/EP2283816A1/en not_active Ceased
- 1995-11-03 AT AT06123277T patent/ATE397441T1/de not_active IP Right Cessation
- 1995-11-03 DE DE69532415T patent/DE69532415T3/de not_active Expired - Lifetime
- 1995-11-03 IL IL14241395A patent/IL142413A/en not_active IP Right Cessation
- 1995-11-03 ES ES95939928T patent/ES2214512T3/es not_active Expired - Lifetime
- 1995-11-03 ES ES04012331T patent/ES2282757T3/es not_active Expired - Lifetime
- 1995-11-06 ZA ZA959367A patent/ZA959367B/xx unknown
-
1996
- 1996-02-09 TW TW085101623A patent/TW425288B/zh not_active IP Right Cessation
-
1997
- 1997-04-10 US US08/833,948 patent/US5958452A/en not_active Expired - Lifetime
-
1999
- 1999-07-22 US US09/358,828 patent/US6335033B2/en not_active Expired - Lifetime
- 1999-07-23 US US09/360,056 patent/US6261599B1/en not_active Expired - Lifetime
-
2001
- 2001-02-06 US US09/777,616 patent/US6743442B2/en not_active Expired - Fee Related
-
2002
- 2002-01-02 US US10/038,867 patent/US6706281B2/en not_active Expired - Fee Related
-
2003
- 2003-09-16 US US10/664,602 patent/US20050089568A1/en not_active Abandoned
- 2003-10-21 US US10/690,389 patent/US20040081694A1/en not_active Abandoned
- 2003-12-23 US US10/745,950 patent/US7510727B2/en not_active Expired - Fee Related
-
2004
- 2004-01-08 IL IL15976604A patent/IL159766A0/xx active IP Right Grant
- 2004-02-27 HK HK05101625A patent/HK1069110A1/xx not_active IP Right Cessation
- 2004-02-27 HK HK05101624A patent/HK1069109A1/xx not_active IP Right Cessation
- 2004-02-27 HK HK04101468.7A patent/HK1059887A1/xx not_active IP Right Cessation
-
2009
- 2009-02-17 US US12/372,460 patent/US20090148517A1/en not_active Abandoned
-
2010
- 2010-03-12 US US12/722,974 patent/US20100172974A1/en not_active Abandoned
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1050306A (ja) * | 1996-07-31 | 1998-02-20 | Toyota Autom Loom Works Ltd | 水素吸蔵合金電極の製造方法 |
JP2013241461A (ja) * | 1999-10-29 | 2013-12-05 | Euro-Celtique Sa | 制御放出ヒドロコドン処方 |
JP2003513032A (ja) * | 1999-10-29 | 2003-04-08 | ユーロ−セルティーク,エス.エイ. | 制御放出ヒドロコドン処方 |
JP2017008089A (ja) * | 1999-10-29 | 2017-01-12 | ユーロ−セルティーク エス.エイ. | 制御放出ヒドロコドン処方 |
JP2015131837A (ja) * | 1999-10-29 | 2015-07-23 | ユーロ−セルティーク エス.エイ. | 制御放出ヒドロコドン処方 |
JP2007084568A (ja) * | 1999-10-29 | 2007-04-05 | Euro-Celtique Sa | 制御放出ヒドロコドン処方 |
JP2015007112A (ja) * | 2000-10-30 | 2015-01-15 | ユーロ−セルティーク エス.エイ. | ヒドロコドン放出制御製剤 |
JP2012167106A (ja) * | 2000-10-30 | 2012-09-06 | Euro-Celtique Sa | ヒドロコドン放出制御製剤 |
JP2008231110A (ja) * | 2000-10-30 | 2008-10-02 | Euro-Celtique Sa | ヒドロコドン放出制御製剤 |
JP2017160250A (ja) * | 2000-10-30 | 2017-09-14 | ユーロ−セルティーク エス.エイ. | ヒドロコドン放出制御製剤 |
JP2016053074A (ja) * | 2000-10-30 | 2016-04-14 | ユーロ−セルティーク エス.エイ. | ヒドロコドン放出制御製剤 |
JP2010100641A (ja) * | 2000-12-26 | 2010-05-06 | Lab Servier | イバブラジン制御放出のための熱成形可能な固形医薬組成物 |
JP2009108083A (ja) * | 2001-05-02 | 2009-05-21 | Euro-Celtique Sa | 一日に一回のオキシコドン製剤 |
JP2017114899A (ja) * | 2001-05-02 | 2017-06-29 | ユーロ−セルティーク エス.エイ. | 一日に一回のオキシコドン製剤 |
JP2004528338A (ja) * | 2001-05-02 | 2004-09-16 | ユーロ−セルティーク,エス.エイ. | 一日に一回のオキシコドン製剤 |
JP2015180669A (ja) * | 2001-05-02 | 2015-10-15 | ユーロ−セルティーク エス.エイ. | 一日に一回のオキシコドン製剤 |
JP4656815B2 (ja) * | 2001-05-02 | 2011-03-23 | ユーロ−セルティーク エス.エイ. | 一日に一回のオキシコドン製剤 |
JP2013189461A (ja) * | 2001-05-02 | 2013-09-26 | Euro-Celtique Sa | 一日に一回のオキシコドン製剤 |
JP2015083616A (ja) * | 2002-09-23 | 2015-04-30 | アルケルメス ファーマ アイルランド リミテッドAlkermes Pharma Ireland Limited | 乱用抵抗性の医薬組成物 |
JP2012021024A (ja) * | 2002-09-23 | 2012-02-02 | Elan Pharma Internatl Ltd | 乱用抵抗性の医薬組成物 |
JP2006502192A (ja) * | 2002-09-23 | 2006-01-19 | ベリオン インコーポレイテッド | 乱用抵抗性の医薬組成物 |
JP2007520429A (ja) * | 2003-06-27 | 2007-07-26 | ユーロ−セルティーク エス.エイ. | マルチ微粒子 |
JP2013209387A (ja) * | 2003-06-27 | 2013-10-10 | Euro-Celtique Sa | マルチ微粒子 |
JP2012193186A (ja) * | 2004-02-12 | 2012-10-11 | Euro-Celtique Sa | 放出制御製剤処方物、単位用量形態、乾燥顆粒、マルチ粒子、調製方法、共重合体の使用、および製剤処方物における耐改ざん性を付与する方法 |
JP2008504327A (ja) * | 2004-07-01 | 2008-02-14 | グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 乱用に対して保護された経口剤形 |
JP2013100306A (ja) * | 2005-01-28 | 2013-05-23 | Euro-Celtique Sa | 耐アルコール性剤形 |
JP2008528654A (ja) * | 2005-02-04 | 2008-07-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 遅延放出性を有する耐破壊性の投薬形 |
JP2009513717A (ja) * | 2005-10-31 | 2009-04-02 | アルザ・コーポレーシヨン | オピオイド徐放性経口投与製剤に対するアルコール誘発の用量ダンピングの軽減方法 |
JP2009523833A (ja) * | 2006-01-21 | 2009-06-25 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 乱用薬剤送達のための製剤および方法 |
JP2013231080A (ja) * | 2006-05-22 | 2013-11-14 | Biohit Oyj | 胃内でアセトアルデヒドを結合するための組成物および方法 |
JP2009538832A (ja) * | 2006-05-22 | 2009-11-12 | ビオヒット・ユルキネン・オサケユキテュア | 胃内でアセトアルデヒドを結合するための組成物および方法 |
JP2010519236A (ja) * | 2007-02-22 | 2010-06-03 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 胃液抵抗性の作用物質−マトリックスを有しているペレット |
JP2014114310A (ja) * | 2007-06-08 | 2014-06-26 | Bayer Intellectual Property Gmbh | 味のマスキングが改善された押出物 |
JP2010529059A (ja) * | 2007-06-08 | 2010-08-26 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 味のマスキングが改善された押出物 |
JP2011510048A (ja) * | 2008-01-24 | 2011-03-31 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 低減したアルコール相互作用を有する乱用抵抗性溶融押出製剤 |
JP2012502968A (ja) * | 2008-09-18 | 2012-02-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | ポリ(ε−カプロラクトン)を含む医薬剤形 |
JP2013537915A (ja) * | 2010-09-24 | 2013-10-07 | キューアールエックスファーマ リミテッド | オピオイドの制御放出製剤 |
JP2014532651A (ja) * | 2011-10-26 | 2014-12-08 | ケムファーム・インコーポレーテッド | ヒドロモルホンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体、そのプロドラッグ、製造法及び使用 |
JP2016504349A (ja) * | 2012-12-31 | 2016-02-12 | サムヤン バイオファーマシューティカルズ コーポレイション | 溶融押出された放出制御用薬学組成物、およびこれを含む経口用製剤 |
US10143659B2 (en) | 2012-12-31 | 2018-12-04 | Samyang Biopharmaceutical Corporation | Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3186064B2 (ja) | 溶融押出しによる経口投与可能なオピオイド製剤 | |
JP6240279B2 (ja) | 制御放出ヒドロコドン処方 | |
JP5960089B2 (ja) | マルチ微粒子 | |
JP4997109B2 (ja) | 用量比例的な定常状態caveおよび定常状態auc、ならびに、用量比例よりも小さい単回投与cmaxを有するオピオイド投薬形態物 | |
AU747389B2 (en) | Melt-extruded orally administrable opioid formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090511 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100511 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110511 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110511 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120511 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130511 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130511 Year of fee payment: 12 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |